Glycaemic control and control of risk factors in diabetes patients in an ophthalmology clinic: What lessons have we learned from the UKPDS and DCCT studies?

Acta Ophthalmologica Scandinavica

Volumn 85, Issue 7, 2007, Pages 772-776

  Higgins, Gareth T ^a   Khan, Javeed ^a   Pearce, Ian A ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Control; Diabetes; Eye; Hypertension; Risk Factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PERINDOPRIL; PRAVASTATIN; QUINAPRIL; RAMIPRIL; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; GLYCEMIC INDEX; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 35448954482     PISSN: 13953907     EISSN: 16000420     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2007.00944.x     Document Type: Article

References (21)

1. Bamashmus MA, Matlhaga B & Dutton GN (2004): Causes of blindness and visual impairment in the west of Scotland. Eye 18: 257-261.
2. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z & Fuller JH (1998): Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 351: 28-31.
3. Chew EY, Klein ML, Ferris FL III, Remaley NA, Murphy RP, Chantry K, Hoogwerf BJ & Miller D (1996): Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. (ETDRS 22). Arch Ophthalmol 114: 1079-1084.
4. Chew EY, Klein ML, Murphy RP, Remaley NA & Ferris FL III (1995): Effects of aspirin on vitreous/preretinal haemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study Report 20. Arch Ophthalmol 113: 52-55.
5. DAMAD Study Group (1989): Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicentre randomized controlled clinical trial. Diabetes 38: 491-498.
6. Dodson PM & Gibson JM (1991): Longterm follow-up of and underlying medical conditions in patients with diabetic exudative maculopathy. Eye 5: 699-703.
7. Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group (1991): Effects of aspirin treatment on diabetic retinopathy. ETDRS Report 8. Ophthalmology 98: 757-765.
8. El-Atat F, McFarlane SI & Sowers JR (2004): Diabetes, hypertension, and cardiovascular derangements: Pathophysiology and management. Curr Hypertens Rep 6: 215-223.
9. HOPE Study Investigators (2000): Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus; results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259.
10. Hove MN, Kristensen JK, Lauritzen T & Bek T (2004): Quantitative analysis of retinopathy in type 2 diabetes: Identification of prognostic parameters for developing visual loss secondary to diabetic maculopathy. Acta Ophthalmol Scand 82: 679-685.
11. Hove MN, Kristensen JK, Lauritzen T & Bek T (2006): The relationships between risk factors and the distribution of retinopathy lesions in type 2 diabetes. Acta Ophthalmol Scand 84: 619-623.
12. Keech A, Simes RJ, Barter P et al. (2005): Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomized controlled trial. Lancet 366: 1849-1861.
13. Knopp RH, d'Emden M, Smilde JG & Pocock SJ (2006): Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29: 1478-1485.
14. Matthews DR, Stratton IM, Aldington SJ, Holman RR & Kohner EM (2004): UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 122: 1631-1640.
15. Neil HA, DeMicco DA, Luo D et al. (2006): Analysis of efficacy and safety in patients aged 65-75 years at randomization. Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 29: 2378-2384.
16. Olafsdottir E, Andersson DK & Stefansson E (2007): Visual acuity in a population with regular screening for type 2 diabetes mellitus and eye disease. Acta Ophthalmol Scand 85: 40-45.
17. Prisant LM (2004): Clinical trials and lipid guidelines for type 2 diabetes. J Clin Pharmacol 44: 423-430.
18. TIMAD Study Group (1990): Ticlopidine treatment reduces the progression of non-proliferative diabetic retinopathy. Arch Ophthalmol 108: 1577-1583.
19. UK Prospective Diabetes Study (UKPDS) Group (1998a): Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 352: 837-853.
20. UK Prospective Diabetes Study (UKPDS) Group (1998b): Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 317: 703-712.
21. Zhang L, Krzentowski G, Albert A & Lefebvre PJ (2001): Risk of developing diabetic retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 24: 1275-1279.